There are many challenges small and medium sized businesses must overcome in clinical research. Credit: SFIO CRACHO via Shutterstock. The pharma sector is at a crossroads, with major challenges for ...

This month, pharma companies have announced plans to increase the prices of more than 250 branded drugs in the US.

Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.

In a new webinar, industry experts explore how innovative technology and direct patient communication are transforming medication adherence in the UK.

CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum depression.

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders.

IFF Pharma Solutions is a winner in the Marketing category in the 2024 Pharmaceutical Technology Excellence Awards.

Leading CRDMO Syngene is a Triple Category Award winner in the 2024 Pharmaceutical Technology Excellence Awards.

Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...